Senate will likely confirm Tavenner, Baucus says

Share this article:
Senate Finance Committee Chairman Max Baucus (D-MT)
Senate Finance Committee Chairman Max Baucus (D-MT)

The Senate Finance Committee will hold a confirmation hearing for Marilyn Tavenner, the White House's nominee to head the Centers for Medicare & Medicaid Services. The committee's chairman, Sen. Max Baucus (D-MT), told the Bureau of National Affairs the hearing would take place “soon.”

Tavenner has been acting CMS administrator since Donald Berwick's departure in December 2011. Her appointment expired at the end of the 112th Congress on Jan. 3. President Barack Obama renominated her to head the agency on Feb. 7.

Baucus declined to hold a confirmation hearing following Tavenner's initial appointment, citing strong opposition. A confirmation fight might also have brought the Affordable Care Act under fire. However, Tavenner has won bipartisan support and Baucus believes she will likely be confirmed, according to BNA.

Mark Parkinson, president and CEO of AHCA/NCAL, called on the Senate to confirm Tavenner, saying she is “the right leader for the job.” Other prominent voices in long-term care, including Alliance for Quality Nursing Home Care President Alan G. Rosenbloom, also endorsed the nomination.

Share this article:
close

Next Article in News

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.